Nitti D, Fabris C, Del Favero G, Farini R, Grassi F, Farini A, Baccaglini U, Pedrazzoli S, Piccoli A, Lise M, Naccarato R
Digestion. 1982;25(4):258-62. doi: 10.1159/000198842.
Serum ferritin, described as increased in patients with pancreatic cancer, was studied in 109 subjects by an immunoradiometric technique in order to assess its reliability in detecting pancreatic malignancy. A significant increase of serum ferritin was found in pancreatic cancer as compared to controls (p less than 0.01), to calcifying (p less than 0.05), non-calcifying (p less than 0.05), and recurrent (p less than 0.01) chronic pancreatitis. Nevertheless, high levels of serum ferritin were found in 10 out of the 36 chronic pancreatitis patients and in 10 out of the 26 patients with non-pancreatic diseases, whilst values within the normal range were detected in 6 out of the 22 pancreatic cancer patients. These data suggest that serum ferritin, although frequently increased in pancreatic cancer, cannot be considered a marker of pancreatic malignancy.
血清铁蛋白在胰腺癌患者中被描述为升高，为评估其在检测胰腺恶性肿瘤方面的可靠性，采用免疫放射分析技术对109名受试者进行了研究。与对照组相比，胰腺癌患者血清铁蛋白显著升高（p<0.01），与钙化性（p<0.05）、非钙化性（p<0.05）和复发性（p<0.01）慢性胰腺炎患者相比也显著升高。然而，36例慢性胰腺炎患者中有10例血清铁蛋白水平升高，26例非胰腺疾病患者中有10例升高，而22例胰腺癌患者中有6例检测值在正常范围内。这些数据表明，血清铁蛋白虽然在胰腺癌中经常升高，但不能被视为胰腺恶性肿瘤的标志物。
